期刊文献+

92例分化型甲状腺癌^(131)I治疗临床分析 被引量:12

Clinical Efficacy of ^(131)I Treatment in 92 Cases of Differentiated Thyroid Cancer
原文传递
导出
摘要 目的对92例分化型甲状腺癌术后131I治疗的临床效果进行分析。方法 92例分化型甲状腺癌患者术后行131I清甲治疗,剂量为50~150 m Ci,25例未发现转移患者治疗1~2次后定期随访,61例有远处转移患者长期阶段性治疗,每次给予150~200 mC i,每次治疗间隔6个月,少数病例间隔6~12个月,治疗中6例失随访,11例因病灶不摄取131I放弃治疗或病情恶化、死亡。合并转移患者治疗疗效判断:①治愈;②好转或稳定;③无效或恶化。患者随访期1~9年。结果 92例DTC患者清甲治疗后一次清甲完全者75例(87.2%),61例转移患者治疗后治愈者14例(23.0%),好转36例(59.0%),11例治疗无效。治疗期间未见严重毒副作用。结论分化型甲状腺癌患者术后131I治疗能够有效降低复发和转移,对于合并转移患者疗效较为满意,同时应加强宣传,提倡合理规范手术,提高DTC患者术后131I治疗比例。 Objective To investigate the clinical efficacy of 131 I treatment for differentiated thyroid cancer.Methods Ninety two cases of differentiated thyroid cancer received 131 I treatment after thyroidectomy with doses of 50-150 mCi per treatment.25 patients without metastases were treated one or two times and followed up regularly;61 patients with remote metastases received long-term periodic 131 I treatment,with doses of 150-200 mCi per treatment and time intervals of 6 months,several cases with time intervals of 6-12 months.There were 6 patients lost to follow-up.11 patients were excluded from further 131 I therapy due to absence of 131 I up take by the metastases or deterioration,death.Assessment of metastases therapeutic results:①cured;②improved or controlled;③none effective.The follow-up time ranged from 1 to 9 years.Results 92 cases underwent 131 I-ablating therapy for remnant thyroid with 75 patients(87.2%) achieved successful thyroid remnant ablation at first dose.Among all 61 patients with remote metastases after 131 I treatment,16 patients(23.0 %) were completely cured,36 patients(59.0 %) were improved and 11 patients were none effective.All patients had no serious adverse reactions during the treatment.Conclusion 131 I treatment in DCT patients after thyroidectomy may effectively reduce tumor relapse and metastasis and had obtained a more satisfactory curative effect for the patients with metastases.At the same time we should strengthen the propaganda,advocate rational surgery and improve 131 I treatment proportion of the DTC patients after thyroidectomy.
出处 《中华全科医学》 2011年第10期1517-1519,共3页 Chinese Journal of General Practice
关键词 甲状腺肿瘤 放射性碘同位素 放射疗法 Thyroid neoplasms Iodine radioisotopes Radiotherapy
  • 相关文献

参考文献10

二级参考文献36

  • 1管昌田,于南,潘明志,匡安仁,谭天秩.分化好的甲状腺癌转移灶的^(131)I治疗[J].中华核医学杂志,1995,15(1):32-34. 被引量:22
  • 2Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing[J] ? Ann Surg Oncol, 2004, 11( 12): 1093 - 1097.
  • 3Sciuto R, Romano L, Marandino F, et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution[J]. Ann One, 2009, 20(10) : 1728 - 1735.
  • 4Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2006, 91(1) : 313 -319.
  • 5Baudin E, Schlumberger M. New therapeutic approachea for metastatic thyroid carcinoma [ ] ]. Lancet Oncol, 2007, 8 (2) : 148 - 156.
  • 6Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy [ J]. J Clin Endocrinol Metab, 2006, 91 (8) : 2892 - 2899.
  • 7Mazzaferri EL, Jhiang SM, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[ J]. Am J Med, 1994, 97(5) : 418 -428.
  • 8Utiger RD. Follow-up of patients with thyroid carcinoma[J]. N Engl J Med, 1997, 337:928-930.
  • 9Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer [ J]. Eur J Nucl Med Mol Imaging, 2008, 35(10): 1941 -1959.
  • 10Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [ J]. Thyroid, 2009, 19 (11) :1167 -1214.

共引文献105

同被引文献104

  • 1陈福进,李秋梨,曾宗渊,宋明,杨安奎,张诠.分化型甲状腺癌的治疗及影响复发的因素分析[J].癌症,2004,23(11):1311-1316. 被引量:50
  • 2孙作忠,宁尚义,张丹枫.碘-131治疗甲状腺疾病的辐射防护问题[J].中国辐射卫生,2005,14(3):203-203. 被引量:16
  • 3陆汉魁,余永利,罗全勇,陈立波,朱瑞森.^(131)I治疗分化型甲状腺癌合并远处转移的疗效及影响因素[J].上海第二医科大学学报,2005,25(12):1263-1266. 被引量:29
  • 4陈雨信,曾庆东.甲状腺癌的内分泌治疗[J].临床外科杂志,2006,14(3):179-180. 被引量:3
  • 5李少林.核医学[M].5版.北京:人民卫生出版社,2002:352-356.
  • 6李少林.核医学第5版[M].北京:人民卫生出版社,2002.380-382.
  • 7Cooper D S, Doherty G M, Haugen B R, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 8Tuttle R M, Hunt J P, Olson J A, et al. NCCN clinical practice guidelines in oncology, thyroid carcinoma. Version 2.0. 2012 [EB/ OL]. (2012-02-03) [2012-09-23]. http://www. nccn. org/ professionals/physician_gls/f_guidelines. asp # thyroid.
  • 9Miller B S,Doherty G M. An examination of recently revised differ entiated thyroid cancer guidelines [J]. Curr Opin Oncol, 2011,23 (1):1-6.
  • 10Sacks W,Fung C H,Chang J T,et al. The effect iveness of radioactive iodine for treatment of low-risk thyroid cancer:asystematic analysis of the peer-reviewed literature from 1966 to April 2008 [J]. Thyroid,2010,20(11) :1235-1245.

引证文献12

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部